Cargando…
Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies
HIV-1 clade C envelope immunogens that elicit both neutralizing and non-neutralizing V1V2-scaffold-specific antibodies (protective correlates from RV144 human trial) are urgently needed due to the prevalence of this clade in the most impacted regions worldwide. To achieve this, we introduce structur...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982139/ https://www.ncbi.nlm.nih.gov/pubmed/35235790 http://dx.doi.org/10.1016/j.celrep.2022.110436 |
_version_ | 1784681742679932928 |
---|---|
author | Sahoo, Anusmita Hodge, Edgar A. LaBranche, Celia C. Styles, Tiffany M. Shen, Xiaoying Cheedarla, Narayanaiah Shiferaw, Ayalnesh Ozorowski, Gabriel Lee, Wen-Hsin Ward, Andrew B. Tomaras, Georgia D. Montefiori, David C. Irvine, Darrell J. Lee, Kelly K. Amara, Rama Rao |
author_facet | Sahoo, Anusmita Hodge, Edgar A. LaBranche, Celia C. Styles, Tiffany M. Shen, Xiaoying Cheedarla, Narayanaiah Shiferaw, Ayalnesh Ozorowski, Gabriel Lee, Wen-Hsin Ward, Andrew B. Tomaras, Georgia D. Montefiori, David C. Irvine, Darrell J. Lee, Kelly K. Amara, Rama Rao |
author_sort | Sahoo, Anusmita |
collection | PubMed |
description | HIV-1 clade C envelope immunogens that elicit both neutralizing and non-neutralizing V1V2-scaffold-specific antibodies (protective correlates from RV144 human trial) are urgently needed due to the prevalence of this clade in the most impacted regions worldwide. To achieve this, we introduce structure-guided changes followed by consensus-C-sequence-guided optimizations at the V2 region to generate UFO-v2-RQH(173) trimer. This improves the abundance of well-formed trimers. Following the immunization of rabbits, the wild-type protein fails to elicit any autologous neutralizing antibodies, but UFO-v2-RQH(173) elicits both autologous neutralizing and broad V1V2-scaffold antibodies. The variant with a 173Y modification in the V2 region, most prevalent among HIV-1 sequences, shows decreased ability in displaying a native-like V1V2 epitope with time in vitro and elicited antibodies with lower neutralizing and higher V1V2-scaffold activities. Our results identify a stabilized clade C trimer capable of eliciting improved neutralizing and V1V2-scaffold antibodies and reveal the importance of the V2 region in tuning this. |
format | Online Article Text |
id | pubmed-8982139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-89821392022-04-05 Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies Sahoo, Anusmita Hodge, Edgar A. LaBranche, Celia C. Styles, Tiffany M. Shen, Xiaoying Cheedarla, Narayanaiah Shiferaw, Ayalnesh Ozorowski, Gabriel Lee, Wen-Hsin Ward, Andrew B. Tomaras, Georgia D. Montefiori, David C. Irvine, Darrell J. Lee, Kelly K. Amara, Rama Rao Cell Rep Article HIV-1 clade C envelope immunogens that elicit both neutralizing and non-neutralizing V1V2-scaffold-specific antibodies (protective correlates from RV144 human trial) are urgently needed due to the prevalence of this clade in the most impacted regions worldwide. To achieve this, we introduce structure-guided changes followed by consensus-C-sequence-guided optimizations at the V2 region to generate UFO-v2-RQH(173) trimer. This improves the abundance of well-formed trimers. Following the immunization of rabbits, the wild-type protein fails to elicit any autologous neutralizing antibodies, but UFO-v2-RQH(173) elicits both autologous neutralizing and broad V1V2-scaffold antibodies. The variant with a 173Y modification in the V2 region, most prevalent among HIV-1 sequences, shows decreased ability in displaying a native-like V1V2 epitope with time in vitro and elicited antibodies with lower neutralizing and higher V1V2-scaffold activities. Our results identify a stabilized clade C trimer capable of eliciting improved neutralizing and V1V2-scaffold antibodies and reveal the importance of the V2 region in tuning this. 2022-03-01 /pmc/articles/PMC8982139/ /pubmed/35235790 http://dx.doi.org/10.1016/j.celrep.2022.110436 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Article Sahoo, Anusmita Hodge, Edgar A. LaBranche, Celia C. Styles, Tiffany M. Shen, Xiaoying Cheedarla, Narayanaiah Shiferaw, Ayalnesh Ozorowski, Gabriel Lee, Wen-Hsin Ward, Andrew B. Tomaras, Georgia D. Montefiori, David C. Irvine, Darrell J. Lee, Kelly K. Amara, Rama Rao Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies |
title | Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies |
title_full | Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies |
title_fullStr | Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies |
title_full_unstemmed | Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies |
title_short | Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies |
title_sort | structure-guided changes at the v2 apex of hiv-1 clade c trimer enhance elicitation of autologous neutralizing and broad v1v2-scaffold antibodies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982139/ https://www.ncbi.nlm.nih.gov/pubmed/35235790 http://dx.doi.org/10.1016/j.celrep.2022.110436 |
work_keys_str_mv | AT sahooanusmita structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT hodgeedgara structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT labrancheceliac structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT stylestiffanym structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT shenxiaoying structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT cheedarlanarayanaiah structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT shiferawayalnesh structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT ozorowskigabriel structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT leewenhsin structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT wardandrewb structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT tomarasgeorgiad structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT montefioridavidc structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT irvinedarrellj structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT leekellyk structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies AT amararamarao structureguidedchangesatthev2apexofhiv1cladectrimerenhanceelicitationofautologousneutralizingandbroadv1v2scaffoldantibodies |